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TO THE EDITOR—We read with interest
the recent article by Shiels et al in Clini-
cal Infectious Diseases [1]. The study
investigates the relationship between ele-
vation of serum free light chain (FLC), a
biomarker of B-cell dysfunction, and the
risk of opportunistic infections associat-
ed with AIDS among persons infected
with human immunodeﬁciency virus
(HIV). This study was a nested case-
control study with a relatively large
number of prestored specimens. Com-
pared to controls, nonmalignant AIDS
events in HIV-infected individuals were
strongly associated with polyclonal
serum FLC elevation. However, to better
address this issue, we believe that several
points need additional discussion.
First, renal function, a very important
potential confounder, has not been evalu-
ated in this study. It is well accepted that
the absolute serum concentrations of
FLCs in a given patient are inﬂuenced by
the rates of production and renal clear-
ance [2]. Because serum FLC raises as
renal clearance is reduced, it is mandato-
ry to have knowledge of the renal func-
tion of the patients included in the study.
Second, hepatitis C virus is considered
a confounder for the serum FLC eleva-
tion [3, 4], but no information is given
about hepatitis C virus infection in case
patients and controls, and it would be
very interesting to have this additional
information from the authors.
Third, increased circulating polyclonal
FLCs may reﬂect primarily an immuno-
logic defect that is shared among many
inﬂammatory and malignant diseases,
many more of which were considered as
exclusion criteria in this study (here
only Kaposi sarcoma and non-Hodgkin
lymphoma were considered). Thus, for
example, it is possible that developing or
undiagnosed conditions that are charac-
terized by chronic B-cell activation/
dysfunction as autoimmune rheumatic
disorders, diabetes mellitus, inﬂammato-
ry bowel disease, cardiovascular diseases,
and malignancies may have caused the
elevation in the FLC years before AIDS
diagnosis [4, 5].
Around the time of publication of
Shiels et al’s study [1], we also investigat-
ed the association between polyclonal
FLCs and prognostic biomarkers rou-
tinely used in the setting of HIV infec-
tion [6]. In this study, cases were
selected randomly in the cohort among
patients without known confounding co-
morbidities for serum FLC elevation.
Indeed, in our series, patients had data
of HIV load and nearly all samples were
collected in the era of highly active anti-
retrovial therapy, so we were able to
evaluate the association of time with a
suppressed viral load and with CD4 cell
count achieved on combination antire-
troviral therapy (cART). Notably, we
found that polyclonal FLCs above the
upper limit of normal are strongly corre-
lated with shorter time of undetectable
HIV viremia, higher viral load, and
lower CD4 cell count at sample. In any
case, the association with AIDS-deﬁning
opportunistic infections did not reach
signiﬁcance at multivariate logistic re-
gression analysis, probably because of
our small sample size.
Finally, large longitudinal clinical
studies with precise selection criteria
should be performed before the mea-
surement of polyclonal FLCs can be
considered as a useful tool to monitor
ongoing immune activation and dys-
function in HIV-positive patients, espe-
cially those with comorbidities on cART.
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